- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03515343
Optivista : I-SCAN OE for Optical Diagnosis of Small Colon Polyps (Optivista)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The benefit of colonoscopy screening is based on the detection and removal of polyps neoplastic. However, the vast majority of found polyps do not harbor any risk of non-cancer neoplastic. The resection evaluation and histopathology of these polyps are associated with costs while the contribution to cancer prevention is limited. A new technique (Pentax Optivista) based on visual diagnosis of polyps has been introduced to reduce the costs associated with over-screening, and seems to be more efficient than the Pentax iScan technique.
This research project aims to evaluate the new Optivista system compared to the iScan for his optical biopsy performance and interval agreement monitoring with pathology.
This is a prospective clinical trial for which participants are recruited directly from the colonoscopy clinic. The Participants will be randomized to be diagnosed by either Optivista or Pentax iScan. Endoscope withdrawal will be done in iScan 1 mode for patients randomized to iSan and in Optivista OE2 mode for patients randomized to Optivista.
For all polyps detected during the procedure, their size, location and morphology will be recorded according to the Paris classification after which all polyps will be resected per standard practices and sent for histopathologic evaluation.
Polyps that are between 1-10mm in size (diminutive and small polyps), there will be further assessed according to WASP, NICE, SANO and SIMPLE classifications using white light imaging and using an image-enhancing endoscopy technology that enhances visualisation of the polyp surface and vascular patterns.
Concordance between optical diagnosis and pathology monitoring according to recommendations will be presented as proportions with a 95% CI. The features optical polyp diagnostic test for overall diminutive (1-5mm) polyps and by location in the colon (proximal, distal, colon and rectosigmoid segments) will be presented. For outcome measures secondary factors, including factors that may influence the optical diagnosis, proportional estimates with a 95% confidence interval (CI) will be presented. Concordance between strategies is examined using a marginal homogeneity test (Stuart-Maxwell test). For the comparison of proportions, a chi square test or a Fisher's exact two-sided test will be used, as appropriate.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada
- Centre Hospitalier Universitaire de Montréal (CHUM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent
- Aged 45 to 80 years
- Indication for full colonoscopy
Exclusion Criteria:
- Known inflammatory bowel disease
- Active colitis
- Coagulopathy
- Familial polyposis syndrome
- Poor general health defined as an ASA class > 3
- Emergency colonoscopies
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Optical diagnosis with Optivista
Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
|
This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
|
Optical diagnosis with iScan
Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
|
This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concordance of Optical diagnosis with the pathology based reference standard
Time Frame: 12 months
|
The Optical diagnosis of polyps using Optivista or iScan will be compared with the pathology based reference standard.
|
12 months
|
Rate of polyps detected of both of the technologies (Optivista and iScan) for Optical diagnosis
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative predictive value of rectosigmoid neoplastic polyps.
Time Frame: 12 months
|
Secondary outcomes and data collection include test characteristics, particularly the negative predictive value of rectosigmoid neoplastic polyps.
|
12 months
|
Concordance of biopsies with WASP classification
Time Frame: 12 months
|
Verification of concordance (yes/no) between histopathological results (biopsies) and WASP classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
|
12 months
|
Concordance of biopsies and SIMPLE classification
Time Frame: 12 months
|
Verification of concordance (yes/no) between histopathological results (biopsies) and SIMPLE classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
|
12 months
|
Concordance of biopsies and SANO classification
Time Frame: 12 months
|
Verification of concordance (yes/no) between histopathological results (biopsies) and SANO classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
|
12 months
|
Concordance of biopsies and NICE classification
Time Frame: 12 months
|
Verification of concordance (yes/no) between histopathological results (biopsies) and NICE classification for polyps up to 10mm in size in conjunction with iScan and Optivista (depending on randomization).
|
12 months
|
Surveillance recommendation following the colonoscopy
Time Frame: 12 months
|
The proportion of patients for whom an immediate surveillance recommendation following the colonoscopy can be directly provided for each approach and how often histopathology polyp examination would have been avoided when using each strategy will be examined.
|
12 months
|
Evaluate Polyp-Based Resect and Discard model
Time Frame: 12 months
|
Surveillance interval agreement of the PBRD strategy compared with pathology-based management according to the 2020 USMSTF guidelines.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel von Renteln, MD, PhD, Centre Hospitalier Universitaire de Montréal, Research Center (CRCHUM)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17.135
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colo-rectal Cancer
-
Istituto Scientifico Romagnolo per lo Studio e...Istituto Oncologico Romagnolo (IOR)Recruiting
-
Chinese University of Hong KongUnknown
-
Fundación para el Fomento de la Investigación Sanitaria...UnknownNutrition Disorders | Colo-rectal Cancer
-
University of Roma La SapienzaCompletedColo-rectal Anastomosis Dehiscence
-
Region Örebro CountyActive, not recruitingColo-rectal Cancer | Gastrointestinal DiseaseSweden
-
Mathieu PiocheRecruiting
-
University of FloridaNational Cancer Institute (NCI)Completed
-
Montreal General HospitalRecruitingThe Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation PeriodSurgery | Colo-rectal CancerCanada
-
Thomas Jefferson UniversityCompletedAnesthesia | Colo-rectal CancerUnited States
-
Assiut UniversityUnknownRecurrence | Colo-rectal Cancer
Clinical Trials on Screening colonoscopy according to resect-and-discard strategy
-
Mỹ Đức HospitalRecruitingInfertility | IVF | Development, Child | IVMVietnam
-
Auxilio Mutuo Cancer CenterSanofiUnknown